116 related articles for article (PubMed ID: 38656148)
1. Moving Beyond Isothiocyanates: A Look at the Stability of Conjugation Links Toward Radiolysis in
Vizier R; Adumeau P; Moreau M; Goncalves V; Denat F
Bioconjug Chem; 2024 May; 35(5):633-637. PubMed ID: 38656148
[TBL] [Abstract][Full Text] [Related]
2. Tripodal tris(hydroxypyridinone) ligands for immunoconjugate PET imaging with (89)Zr(4+): comparison with desferrioxamine-B.
Ma MT; Meszaros LK; Paterson BM; Berry DJ; Cooper MS; Ma Y; Hider RC; Blower PJ
Dalton Trans; 2015 Mar; 44(11):4884-900. PubMed ID: 25351250
[TBL] [Abstract][Full Text] [Related]
3. DFO-Km: A Modular Chelator as a New Chemical Tool for the Construction of Zirconium-89-Based Radiopharmaceuticals.
Salih AK; Dominguez Garcia M; Raheem SJ; Ahiahonu WK; Price EW
Inorg Chem; 2023 Dec; 62(50):20806-20819. PubMed ID: 37751491
[TBL] [Abstract][Full Text] [Related]
4. Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for
Raavé R; Sandker G; Adumeau P; Jacobsen CB; Mangin F; Meyer M; Moreau M; Bernhard C; Da Costa L; Dubois A; Goncalves V; Gustafsson M; Rijpkema M; Boerman O; Chambron JC; Heskamp S; Denat F
Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1966-1977. PubMed ID: 31161258
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for
Vugts DJ; Klaver C; Sewing C; Poot AJ; Adamzek K; Huegli S; Mari C; Visser GWM; Valverde IE; Gasser G; Mindt TL; van Dongen GAMS
Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):286-295. PubMed ID: 27573793
[TBL] [Abstract][Full Text] [Related]
6. Total-Body PET and Highly Stable Chelators Together Enable Meaningful
Berg E; Gill H; Marik J; Ogasawara A; Williams S; van Dongen G; Vugts D; Cherry SR; Tarantal AF
J Nucl Med; 2020 Mar; 61(3):453-460. PubMed ID: 31562219
[TBL] [Abstract][Full Text] [Related]
7. p-SCN-Bn-HOPO: A Superior Bifunctional Chelator for (89)Zr ImmunoPET.
Deri MA; Ponnala S; Kozlowski P; Burton-Pye BP; Cicek HT; Hu C; Lewis JS; Francesconi LC
Bioconjug Chem; 2015 Dec; 26(12):2579-91. PubMed ID: 26550847
[TBL] [Abstract][Full Text] [Related]
8. Radiolabelling of the octadentate chelators DFO* and oxoDFO* with zirconium-89 and gallium-68.
Brandt M; Cowell J; Aulsebrook ML; Gasser G; Mindt TL
J Biol Inorg Chem; 2020 Aug; 25(5):789-796. PubMed ID: 32661784
[TBL] [Abstract][Full Text] [Related]
9. A comparison of DFO and DFO* conjugated to trastuzumab-DM1 for complexing
Cho H; Al-Saden N; Lam H; Möbus J; Reilly RM; Winnik MA
Nucl Med Biol; 2020; 84-85():11-19. PubMed ID: 31931305
[TBL] [Abstract][Full Text] [Related]
10.
Heskamp S; Raavé R; Boerman O; Rijpkema M; Goncalves V; Denat F
Bioconjug Chem; 2017 Sep; 28(9):2211-2223. PubMed ID: 28767228
[TBL] [Abstract][Full Text] [Related]
11. Cyclic versus Noncyclic Chelating Scaffold for
Summer D; Garousi J; Oroujeni M; Mitran B; Andersson KG; Vorobyeva A; Löfblom J; Orlova A; Tolmachev V; Decristoforo C
Mol Pharm; 2018 Jan; 15(1):175-185. PubMed ID: 29160082
[TBL] [Abstract][Full Text] [Related]
12. Multifunctional Desferrichrome Analogues as Versatile
Adams CJ; Wilson JJ; Boros E
Mol Pharm; 2017 Aug; 14(8):2831-2842. PubMed ID: 28665620
[TBL] [Abstract][Full Text] [Related]
13. Design, Synthesis, and Evaluation of DFO-Em: A Modular Chelator with Octadentate Chelation for Optimal Zirconium-89 Radiochemistry.
Salih AK; Raheem SJ; Garcia MD; Ahiahonu WK; Price EW
Inorg Chem; 2022 Dec; 61(51):20964-20976. PubMed ID: 36516446
[TBL] [Abstract][Full Text] [Related]
14. A Systematic Evaluation of Antibody Modification and
Sharma SK; Glaser JM; Edwards KJ; Khozeimeh Sarbisheh E; Salih AK; Lewis JS; Price EW
Bioconjug Chem; 2021 Jul; 32(7):1177-1191. PubMed ID: 32197571
[TBL] [Abstract][Full Text] [Related]
15. p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging.
Perk LR; Vosjan MJ; Visser GW; Budde M; Jurek P; Kiefer GE; van Dongen GA
Eur J Nucl Med Mol Imaging; 2010 Feb; 37(2):250-9. PubMed ID: 19763566
[TBL] [Abstract][Full Text] [Related]
16. Development and in vitro evaluation of new bifunctional
Klasen B; Lemcke D; Mindt TL; Gasser G; Rösch F
Nucl Med Biol; 2021; 102-103():12-23. PubMed ID: 34242949
[TBL] [Abstract][Full Text] [Related]
17. Lysine-Directed Site-Selective Bioconjugation for the Creation of Radioimmunoconjugates.
Sarrett SM; Rodriguez C; Rymarczyk G; Hosny MM; Keinänen O; Delaney S; Thau S; Krantz BA; Zeglis BM
Bioconjug Chem; 2022 Sep; 33(9):1750-1760. PubMed ID: 35946495
[TBL] [Abstract][Full Text] [Related]
18. The Influence of Glycans-Specific Bioconjugation on the FcγRI Binding and
Vivier D; Fung K; Rodriguez C; Adumeau P; Ulaner GA; Lewis JS; Sharma SK; Zeglis BM
Theranostics; 2020; 10(4):1746-1757. PubMed ID: 32042334
[No Abstract] [Full Text] [Related]
19. In Vivo Characterization of Platinum(II)-Based Linker Technology for the Development of Antibody-Drug Conjugates: Taking Advantage of Dual Labeling with
Muns JA; Montserrat V; Houthoff HJ; Codée-van der Schilden K; Zwaagstra O; Sijbrandi NJ; Merkul E; van Dongen GAMS
J Nucl Med; 2018 Jul; 59(7):1146-1151. PubMed ID: 29496986
[TBL] [Abstract][Full Text] [Related]
20.
Fung K; Vivier D; Keinänen O; Sarbisheh EK; Price EW; Zeglis BM
Molecules; 2020 May; 25(10):. PubMed ID: 32429033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
